Mandatory 60-day testing under Rule 45 and timely prosecution to protect Section 25 re-testing rights: failure renders Drugs Act proceedings an abuse of process

Case: C. B. HEALTHCARE, THROUGH ITS AUTHORIZED SIGNATORY SHRI ASHISH KUMAR v. UNION OF INDIA THROUGH DRUG INSPECTOR PUSHPRAJ KUMAR SINGH
Court: Bombay High Court (N.J. Jamadar, J.)
Date: 24-03-2026
Proceeding: Writ Petition under Article 227 seeking quashment of Special Case No. 32 of 2021 (offence under Section 27(d), Drugs & Cosmetics Act, 1940)

Summary of the Judgment

• Prosecution quashed. The High Court set aside the order issuing process dated 28 September 2021 and quashed Special Case No. 32 of 2021.
• Rule 45 breach held serious. Testing/reporting far beyond the 60-day rule (without the Government Analyst seeking extension under the proviso) undermined the prosecution.
• Section 23/25 safeguards frustrated. Failure to send a sample portion to the manufacturer, combined with a complaint filed long after the drug’s expiry, effectively destroyed the manufacturer’s right to seek re-testing; continuation would be a “lame prosecution”.
• Direct cognizance by Sessions Court doubted. The Court found substance in the objection that, absent an express statutory override, Section 193 CrPC bars direct cognizance by a Court of Session for Chapter IV Drugs Act offences.
• Vicarious liability allegations weak but not decisive. Averments against the partners did not strictly spell out their role; however, since prosecution against the firm itself was quashed, the Court did not finally decide this point.

Analysis

1) Precedents Cited and Their Influence

M/s. Quixotic Healthcare and Ors. V/s. State of Maharashtra and Ors.

This Court precedent was relied upon to emphasize that unexplained delay in testing can make the analyst’s conclusion inherently unreliable and that the benefit of such lapse should go to the accused. The High Court treated it as supporting the proposition that delayed testing “dents the prosecution,” particularly where the statutory mechanism for extension is not followed.

Swapnil and Ors. V/s. State of Maharashtra

The decision was used to reinforce Rule 45’s function: analysis within 60 days is linked to accuracy and to the accused’s ability to pursue re-testing. The High Court aligned with this rationale, viewing delay as a structural impairment, not a curable irregularity.

State of Harayana V/s. Brij Lal Mittal and Ors.

The Supreme Court’s articulation of Section 25(3)–(4) was accepted as a correct statement of law: the Government Analyst report becomes conclusive unless timely notice of intent to controvert is given; and the right under Section 25(4) ordinarily presupposes Section 25(3) compliance. The High Court, however, noted that the manufacturer’s position must be examined with attention to whether it actually received the report and sample, and whether delay made re-testing impossible in any event.

Amery Pharmaceuticals And Anr Vs State of Rajasthan

This case was pivotal on the meaning of Section 23(4)(iii) in a distribution chain. The Supreme Court held that, where a sample is taken from a retailer, the Inspector’s obligation is to supply portions to the retailer and to the person disclosed under Section 18A (typically the distributor/wholesaler), not necessarily the manufacturer. Yet, the Supreme Court also adopted a rights-protective reading: a manufacturer who is not entitled “as of right” to the report must still have liberty to challenge the analyst report and may seek Section 25(4) testing through court—subject to delay and feasibility. The High Court used this to frame the manufacturer’s grievance as ultimately turning on whether the statutory “valuable right” became illusory due to delay.

Laborate Pharmaceuticals India Ltd. and Ors. V/s. State of Tamil Nadu

This precedent strongly influenced the outcome. The High Court drew a close analogy: failure to supply the sample portion, coupled with procedural delays, can deny the accused the “valuable right” of Central Laboratory testing; if shelf life has passed, continuing prosecution becomes a “lame prosecution” and is liable to be quashed as an abuse of process.

Medipol Pharmaceutical India Pvt. Ltd. V/s. Post Graduate Institute of Medical Eduation and Research and Anr.

The Supreme Court’s broader principle—across Drugs, Food Adulteration, and Insecticides statutes—was treated as reinforcing the central theme: where the State’s delay causes deterioration/shelf-life issues, thereby frustrating appellate/superior testing rights, punitive consequences cannot stand. The High Court’s reasoning closely tracks this “valuable right + delay attributable to State” framework.

Union of India V/s. Ashok Kumar sharma and Ors.

This decision directly supported the Court’s doubt about direct cognizance by a Court of Session. The Supreme Court explained that, for Chapter IV offences, absent an express statutory authorization, the CrPC committal route applies: a Magistrate takes cognizance and then commits the case; Section 193 CrPC bars direct original cognizance by Sessions Court. The High Court cited this to reject the Respondent’s attempt to rely on a notification to bypass Section 193.

Municipal Corporation of Delhi Vs Ram Kishan Rohtagi

Cited via Brij Lal Mittal, this case was used to reiterate the pleading threshold for vicarious liability: directors cannot be proceeded against on mere designation; complaint must contain material indicating responsibility/in-charge status (subject to the special position of managers/MDs). The High Court applied this reasoning to note that the complaint’s assertions against the partners were largely formulaic.

Lalankumar Singh and Ors Vs State of Maharashtra

The Supreme Court’s emphasis that merely reproducing statutory words (without factual particulars on “how and in what manner” a person was responsible) does not create vicarious criminal liability was invoked to critique the complaint’s sparse allegations against the partners.

2) Legal Reasoning

(A) Rule 45 Drugs Rules, 1945: 60-day timeline treated as peremptory

The Court read Rule 45(1) as mandatory: the Government Analyst shall furnish the report within 60 days of sample receipt. If testing within 60 days is not possible, the proviso provides the only statutory “outlet”: the Government Analyst shall seek extension from the Government, giving specific reasons.

On facts, the sample was sent on 30 November 2016 and the report was issued only on 5/6 July 2017 (about seven months later). The Respondent attempted to justify delay by affidavit (reference/impurity standards not readily available). The Court held this could not cure non-compliance: (i) the explanation must come from the Government Analyst, and (ii) it must be routed through the proviso mechanism. Otherwise, Rule 45’s peremptory design becomes “otiose”.

(B) Section 23(4) / Section 25: “valuable right” of re-testing and the effect of delay

The Court emphasized that the statutory sampling architecture is not a formality; it protects the accused’s ability to challenge an adverse analyst report. Even assuming disputes about whether the manufacturer was the correct recipient of the “third/fourth” portion in this chain, the Court found an independent, decisive defect: the complaint was filed in September 2021, whereas the drug’s expiry was August 2018.

As a result, by the time cognizance/process occurred, the sample’s shelf life had ended years earlier and the trial court could not meaningfully send the sample for Central Laboratory re-testing. Thus, the manufacturer’s re-testing remedy was defeated by “a series of failures and inactions” of the prosecution. Relying on Laborate Pharmaceuticals India Ltd. and Ors. V/s. State of Tamil Nadu and the principle in Medipol Pharmaceutical India Pvt. Ltd. V/s. Post Graduate Institute of Medical Eduation and Research and Anr., the Court held that continuing the prosecution would be an abuse of process.

(C) Cognizance: Section 32 Drugs Act does not override Section 193 CrPC

The High Court reasoned that Section 32(2) (trial by Court not inferior to Sessions) does not, by itself, authorize direct cognizance by the Sessions Court. Without an express statutory override (“notwithstanding … CrPC” style language) or an express provision authorizing direct cognizance, Section 193 CrPC applies, requiring committal by a Magistrate.

The Respondent’s reliance on a notification designating a Special Court under Section 36AB(1) was rejected as inapplicable: (i) the prosecution was under Section 27(d), and (ii) designation of a court to try does not itself create power to take direct cognizance. The reasoning was reinforced by Union of India V/s. Ashok Kumar sharma and Ors..

(D) Vicarious liability under Section 34: pleadings must be more than a statutory incantation

The Court noted that the complaint broadly alleged the partners were responsible for day-to-day activities and release for distribution, but did not clearly explain “how and in what manner” they were in charge and responsible. This was flagged as a weakness in light of State of Harayana V/s. Brij Lal Mittal and Ors. and Lalankumar Singh and Ors Vs State of Maharashtra. However, the Court treated it as non-determinative because the prosecution against the firm itself was unsustainable.

3) Impact

• Stricter enforceability of Rule 45 timelines: The judgment signals that long-delay analyst reports, without extension sought under the proviso, can be treated as fundamentally compromising the prosecution, not merely as an evidentiary issue to be tested at trial.
• Delay in launching prosecution can be fatal where shelf life expires: Investigating agencies must act within a timeframe that preserves the accused’s statutory ability to pursue Central Laboratory re-testing; otherwise, courts may quash proceedings as a “lame prosecution”.
• Procedural path to trial matters: It reiterates that “trial by Sessions” does not automatically mean “direct cognizance by Sessions”. Prosecutors must follow the CrPC committal route unless the Drugs Act expressly provides otherwise.
• Heightened pleading discipline for Section 34 prosecutions: Complaints against partners/directors should contain concrete role-based assertions, reducing the practice of mechanically arraying office-bearers without particulars.

Complex Concepts Simplified

• “Not of standard quality”: A statutory classification under the Drugs Act indicating the sample does not meet prescribed pharmacopoeial/quality standards.
• Rule 45 (Drugs Rules, 1945): Requires the Government Analyst to test/analyse and issue the report within 60 days. If not possible, the Analyst must seek formal extension from the Government with reasons.
• Section 23 sample portions: The sample is split and distributed so that (a) the prosecution can proceed, and (b) affected parties can challenge the report.
• Section 25 “valuable right”: A person facing prosecution can contest an adverse report and seek a superior Central Laboratory test. If delay causes the sample to expire/deteriorate, that right becomes meaningless—courts treat this as serious prejudice.
• “Cognizance”: The legal act by which a court first takes notice of an offence to proceed judicially. Under Section 193 CrPC, Sessions Courts generally cannot take cognizance directly unless a law expressly allows it; they act after committal by a Magistrate.
• Vicarious liability (Section 34): Liability of persons in charge of and responsible for a company/firm’s business for an offence committed by the entity. Courts require role-specific pleadings, not mere designation.

Conclusion

The Bombay High Court’s decision is a procedural-safeguards-centric precedent in Drugs Act prosecutions: it treats Rule 45’s 60-day timeline (and its proviso) as mandatory, and it places decisive weight on whether the prosecution’s conduct preserved the accused’s statutory right to seek re-testing under Section 25. Where prolonged delays—especially those attributable to the State—render re-testing impossible due to shelf-life expiry, the prosecution is liable to be quashed as an abuse of process. The judgment also reinforces that, absent express statutory authorization, Sessions Courts cannot take direct cognizance for Chapter IV offences, and that Section 34 prosecutions require more than formulaic assertions against partners/directors.